Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
The transaction will add ORI-001 to Sanofi’s early-stage pipeline. ORI-001 is a first therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, which entered preliminary clinical studies in Q3 2021.
Lead Product(s): ORI-001
Therapeutic Area: Dermatology Product Name: ORI-001
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 01, 2021
Details:
FRTX-02 is potent, highly selective, and orally bioavailable potential first-in-class DYRK1A inhibitor that aims to restore immune balance by modulating both adaptive and innate immune responses in patients with autoimmune and inflammatory diseases.
Lead Product(s): FRTX-02
Therapeutic Area: Dermatology Product Name: FRTX-02
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
LY3471851/NKTR-358 (rezpegaldesleukin) is a novel, selective regulatory T-cell inducing IL-2 conjugate designed to target immune system imbalance that results from increased levels of inflammatory T cells and reduced numbers and impaired function of regulatory T cells.
Lead Product(s): Rezpegaldesleukin
Therapeutic Area: Dermatology Product Name: NKTR-358
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
RBN-3143, a first-in-class, orally administered, small molecule inhibitor of PARP14, has the potential to be a differentiated therapy for the treatment of numerous inflammatory diseases.
Lead Product(s): RBN-3143
Therapeutic Area: Dermatology Product Name: RBN-3143
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
CBP-174 administered orally, was observed to be safe and well-tolerated across eight dose escalation cohorts evaluated up to a maximum dose of 16 mg or placebo in this randomized, double-blind, placebo-controlled, single ascending dose (SAD) study.
Lead Product(s): CBP-174
Therapeutic Area: Dermatology Product Name: CBP-174
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
VTX958 is an oral, selective allosteric inhibitor of tyrosine kinase 2 (TYK2). TYK2 regulates both innate and adaptive immunity by mediating IFNα, IL-12 and IL-23 signaling.
Lead Product(s): VTX958
Therapeutic Area: Dermatology Product Name: VTX958
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
ICP-488 is a potent and selective TYK2 (tyrosine kinase 2) allosteric inhibitor being developed for the treatment of autoimmune diseases such as psoriasis and inflammatory bowel disease (IBD).
Lead Product(s): ICP-488
Therapeutic Area: Dermatology Product Name: ICP-488
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
LNK01004 is a novel kinase inhibitor for the treatment of psoriasis and has shown good efficacy and safety in preclinical experiments. It has the advantages of restricted distribution to the skin and extremely low exposure in the blood system.
Lead Product(s): LNK01004
Therapeutic Area: Dermatology Product Name: LNK01004
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2022
Details:
DC-806 is an orally-available, small molecule antagonist of the pro-inflammatory cytokine, interleukin-17 (IL-17), which is a validated drug target for the treatment of a variety of autoimmune and inflammatory diseases, including psoriasis.
Lead Product(s): DC-806
Therapeutic Area: Dermatology Product Name: DC-806
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
